The Diagnostic Journey: Blood Work, Electrical Tests, and Genetics

Getting a diagnosis for GMPPB-related disease often involves several different types of tests. Because this condition can look like many other muscle disorders, doctors use a combination of blood work, electrical tests, and genetic analysis to piece together the full picture ^[1][2].

Understanding Your CK Levels

One of the first clues to a muscle disorder is often an elevated level of creatine kinase (CK). This is an enzyme found inside healthy muscle cells; when those cells are damaged or have fragile membranes, the enzyme leaks out into your bloodstream ^[3][4].

While CK can be 2 to 50 times the upper limit of normal in some muscular dystrophy phenotypes, those with predominantly myasthenic features may have normal or only mildly elevated CK ^[1][2]. Surprisingly, your CK levels can be extremely high (sometimes in the thousands) even if your muscle weakness feels relatively mild or if you haven’t been particularly active ^[1][3]. While a high CK level doesn’t tell a doctor which disease you have, it is a strong signal that the muscle membranes are under stress ^[2].

The Difference Between EMG and RNS

If you have muscle weakness, your doctor may order an Electromyography (EMG). This involves a thin needle being placed into the muscle to record its electrical activity ^[1]. While an EMG can show “myopathic” changes (signs that the muscle itself is sick), it may not tell the whole story ^[5][2].

It is vital to ask if your doctor also performed Repetitive Nerve Stimulation (RNS).

• How it works: During RNS, a nerve is stimulated with small electrical pulses several times in a row ^[5].
• What it looks for: In some people with GMPPB mutations, the signal from the nerve to the muscle gets weaker with each pulse. This is called a decrement ^[5][6].
• Why it matters: If an RNS test shows this decrement, it supports impaired neuromuscular transmission (the overlap with Congenital Myasthenic Syndrome (CMS)). However, a decrement must be interpreted with the clinical picture, test technique, and genetic findings; a normal study does not necessarily exclude the overlap ^[5][7].

The Muscle Biopsy: A Look at “Decorations”

A muscle biopsy involves taking a small sample of muscle tissue to examine under a microscope. In GMPPB-related disease, the muscle tissue often shows signs of a dystroglycanopathy ^[8][9].

When specialists stain the tissue sample, they specifically look for alpha-dystroglycan. As discussed on previous pages, this protein needs “sugar decorations” to work. In a biopsy from someone with a GMPPB mutation, those sugar chains are often missing or reduced (hypoglycosylation) ^[8][10]. One marker that specialists may look for is a “mobility shift” in beta-dystroglycan during a laboratory test called a Western blot; this is a supportive finding, but is not by itself specific for GMPPB and a muscle biopsy may not even be necessary if genetic testing is clear ^[8][10].

Genetic Testing: Establishing the Diagnosis

Genetic testing (such as broad NGS panels, exome/genome sequencing, or deletion/duplication testing) is required to confirm the diagnosis ^[1][11]. Because the symptoms of GMPPB-related disease can look like many other conditions, your doctor should order a broad “LGMD panel” or “Neuromuscular panel” that checks many genes at once ^[11].

To confirm a diagnosis of this autosomal recessive condition, the testing must show two things:

1. Pathogenic Variants: You must have pathogenic or likely pathogenic variants in the GMPPB gene. A Variant of Uncertain Significance (VUS) is not proof of disease ^[1][12].
2. “In Trans” Inheritance: It is not enough to just have two different mutations; they must be on different copies of the gene (one from your mother and one from your father). This is called being in trans ^[12][1].

To prove this, doctors often perform segregation analysis, which involves testing your parents’ blood to see which mutation each one carries ^[12][5]. If both mutations were on the same copy of the gene (inherited from only one parent), you would be a “carrier” but likely would not have the disease ^[13]. Confirming that the mutations are “in trans” is a critical final step in your diagnostic journey, though interpretation is complex and a negative panel does not automatically exclude the disease ^[1].